Kotta Sabna, Aldawsari Hibah Mubarak, Badr-Eldin Shaimaa M, Alhakamy Nabil Abdulhafiz, Md Shadab, Nair Anroop B, Deb Pran Kishore
Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Department of Pharmaceutics and Industrial Pharmacy, Cairo University, Cairo, Egypt.
Front Mol Biosci. 2020 Nov 17;7:606393. doi: 10.3389/fmolb.2020.606393. eCollection 2020.
The coronavirus disease-19 (COVID-19) is caused due to the infection by a unique single stranded enveloped RNA virus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The COVID-19 has claimed many lives around the globe, and a promising solution to end this pandemic is still awaited. Till date neither an exact antiviral drug nor a vaccine is available in the market for public use to cure or control this pandemic. Repurposed drugs and supportive measures are the only available treatment options. This systematic review focuses on different treatment strategies based on various clinical studies. The review discusses all the current treatment plans and probable future strategies obtained as a result of a systematic search in PubMed and Science Direct database. All the possible options for the treatment as well as prophylaxis of COVID-19 are discussed. Apart from this, the article provides details on the clinical trials related to COVID-19, which are registered under ClinicalTrials.gov. Potential of drugs based on the previous researches on SARS-CoV, MERS-CoV, Ebola, influenza, etc. which fall under the same category of coronavirus are also emphasized. Information on cell-based and immunology-based approaches is also provided. In addition, miscellaneous therapeutic approaches and adjunctive therapies are discussed. The drug repurposing options, as evidenced from various and models, are also covered including the possible future solutions to this pandemic.
冠状病毒病-19（COVID-19）是由一种独特的单链包膜RNA病毒——严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染所致。COVID-19已在全球夺走众多生命，而终结这场大流行的有效解决方案仍有待探寻。截至目前，市场上尚无用于治疗或控制这一疫情的特效抗病毒药物或疫苗。现有治疗手段仅有药物再利用和支持性措施。本系统评价聚焦于基于各项临床研究的不同治疗策略。该评价讨论了通过对PubMed和科学Direct数据库进行系统检索得出的所有当前治疗方案以及可能的未来策略。探讨了治疗及预防COVID-19的所有可能选项。除此之外，本文还详细介绍了在ClinicalTrials.gov上注册的与COVID-19相关的临床试验。还强调了基于此前对属于同一冠状病毒类别的SARS-CoV、MERS-CoV、埃博拉病毒、流感病毒等研究的药物潜力。也提供了基于细胞和免疫的方法的信息。此外，还讨论了其他治疗方法和辅助治疗。还涵盖了从各种体外和体内模型中得到证实的药物再利用选项，包括针对这一疫情可能的未来解决方案。
